TCT 2017: BIOTRONIK's Orsiro Drug-Eluting Stent Shows Low Five-Year Event Rates in BIOFLOW-II RCT and BIOFLOW-III Registry
DENVER, United States and BUELACH, Switzerland, November 2, 2017 - BIOTRONIK's Orsiro1 drug-eluting stent (DES) demonstr…
DENVER, United States and BUELACH, Switzerland, November 2, 2017 - BIOTRONIK's Orsiro1 drug-eluting stent (DES) demonstr…
BIOTRONIK’s highest performing cardiac resynchronization therapy defibrillator (CRT-D) is now available in Japan. With s…
BIOTRONIK has announced the launch of its Evity cardiac resynchronization therapy pacemaker (CRT-P) in the Japanese mark…
BIOTRONIK’s Pulsar-18 bare metal stent (BMS) has yielded high primary patency in a real-world setting, according to the…
BIOTRONIK has announced the European launch of a new lead for tachycardia therapy that features a helical design for inc…
PRO-Kinetic Energy Cobalt Chromium (CoCr) Coronary Stent System from BIOTRONIK gained FDA approval utilizing results fro…
Patients in Japan are the world’s first to benefit from BIOTRONIK’s Ilivia implantable cardioverter defibrillators (ICDs…
BIOTRONIK has announced that its CardioMessenger Smart device is available for patients in the UK and Ireland. Similar i…
Following recent CE mark approval for BIOTRONIK’s E-Series pacemakers, a UK patient has become the first in Europe to be…
BIOTRONIK, a leader in cardio- and endovascular medical technology, today announced Food and Drug Administration (FDA) a…